Solid Biosciences (SLDB) said late Tuesday the US Food and Drug Administration cleared the company's investigational new drug application for SGT-212 to treat Friedreich's ataxia.
The company expects to begin a phase 1b clinical trial of SGT-212 in H2 with study participants to be followed out to five years after receiving the treatment.
Friedreich's ataxia is a degenerative disease caused by inadequate levels of the frataxin protein.
Solid Biosciences shares rose 13% in after-hours activity.
Price: 4.44, Change: +0.52, Percent Change: +13.27
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。